Emageon year-end revenue increases 97%

Emageon Inc. this week released financial results for the quarter and the year ending December 31, 2004.
   
Revenues increased 77 percent to $16.2 million, compared with $9.2 million in the fourth quarter of FY03. Net loss was $2.2 million, compared with net loss of $1.9 million in the year-ago quarter.  
   
For the year, revenues increased 97 percent to $45.8 million, compared with $23.3 million in FY03. Net loss was reported at $10.5 million, compared with loss of $11.4 million in the year-ago period.
   
Emageon recently completed its initial public offering. Including the over-allotment option, Emageon issued 5.75 million shares of common stock at a price of $13 per share.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup